<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440163</url>
  </required_header>
  <id_info>
    <org_study_id>C3511001</org_study_id>
    <secondary_id>2019-004313-13</secondary_id>
    <nct_id>NCT04440163</nct_id>
  </id_info>
  <brief_title>MenABCWY Noninferiority Study in Healthy Participants ≥10 to &lt;26 Years of Age</brief_title>
  <official_title>A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO &lt;26 YEARS OF AGE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the immunologic noninferiority of MenABCWY to licensed&#xD;
      vaccines Trumenba and MenACWY-CRM (Menveo) by assessing the safety and immunogenicity of&#xD;
      MenABCWY and the comparators in both ACWY-naïve and ACWY-experienced healthy participants ≥10&#xD;
      to &lt;26 years of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">July 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 18, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving at least a 4-fold rise hSBA titer from baseline for each ACWY test strain - Group 1 and 2</measure>
    <time_frame>1 month after Vaccination 2 in Group 1 compared to 1 month after Vaccination 1 in Group 2</time_frame>
    <description>Demonstrate immune response for Men A, C, W, Y after 2 doses of Men ABCWY is non-inferior to immune response after 1 dose of Men ACWY-CRM in naïve participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving at least a 4-fold rise in hSBA titer from baseline for each ACWY test strain - Group 3 and 4</measure>
    <time_frame>1 month after Vaccination 2 in Group 3 compared to 1 month after Vaccination 1 in Group 4</time_frame>
    <description>Demonstrate immune response for Men A, C, W, Y after 2 doses of Men ABCWY is non-inferior to immune response after 1 dose of Men ACWY-CRM in experienced participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving an hSBA titer ≥ LLOQ for all 4 primary MenB test strains combined (composite response), in Groups 1 and 3 combined compared to Groups 2 and 4 combined</measure>
    <time_frame>1 month after Vaccination 2</time_frame>
    <description>Non Inferiority of 2 doses of Men ABCWY compared to 2 doses of Trumenba</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving at least a 4-fold rise in hSBA titer from baseline for each of the 4 primary MenB test strains, in Groups 1 and 3 combined compared to Groups 2 and 4 combined</measure>
    <time_frame>1 month after Vaccination 2</time_frame>
    <description>Non Inferiority of 2 doses of Men ABCWY compared to 2 doses of Trumenba</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting local reactions within 7 days after each vaccination</measure>
    <time_frame>Within 7 days after each vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting systemic events within 7 days after each vaccination</measure>
    <time_frame>Within 7 days after each vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting use of antipyretic medication within 7 days after each vaccination</measure>
    <time_frame>Within 7 days after each vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 SAE within 30 Days after each vaccination</measure>
    <time_frame>Within 30 days after each vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 SAE within 30 Days after any vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 SAE during the vaccination phase</measure>
    <time_frame>During vaccination phase (From study entry through one month after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 SAE during the follow-up phase</measure>
    <time_frame>During Follow-up phase (From one month after 2nd vaccination through 6 months after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 SAE throughout the study.</measure>
    <time_frame>Throughout the study (From study entry through 6 months after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 MAE within 30 Days after each vaccination</measure>
    <time_frame>Within 30 days after each vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 MAE within 30 Days after any vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 MAE during the vaccination phase</measure>
    <time_frame>During vaccination phase (From study entry through one month after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 MAE during the follow-up phase</measure>
    <time_frame>During Follow-up phase (From one month after 2nd vaccination through 6 months after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 MAE throughout the study.</measure>
    <time_frame>Throughout the study (From study entry through 6 months after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 NDCMC within 30 Days after each vaccination</measure>
    <time_frame>Within 30 days after each vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 NDCMC within 30 Days after any vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 NDCMC during the vaccination phase</measure>
    <time_frame>During vaccination phase (From study entry through one month after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 NDCMC during the follow-up phase</measure>
    <time_frame>During Follow-up phase (From one month after 2nd vaccination through 6 months after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 NDCMC throughout the study.</measure>
    <time_frame>Throughout the study (From study entry through 6 months after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 AE 30 Days after each vaccination</measure>
    <time_frame>Within 30 days after each vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 AE 30 Days after any vaccination</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 AE during the vaccination phase</measure>
    <time_frame>During vaccination phase (From study entry through one month after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting at least 1 immediate AE</measure>
    <time_frame>Throughout the study (From the time of vaccine administration until 30 minutes post vaccine administration)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who missed days of school or work because of AEs</measure>
    <time_frame>Throughout the study (From study entry through 6 months after 2nd vaccination)</time_frame>
    <description>Describe the safety profile of MenABCWY</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving at least a 4-fold rise in hSBA titer from baseline for each ACWY test strain in Group 1 compared to Group 2.</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
    <description>Non-inferiority of immune response after 1 dose of Men ABCWY compared to 1 dose of Men ACWY-CRM in naïve participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving at least a 4-fold rise in hSBA titer from baseline for each ACWY test strain in Group 3 compared to Group 4.</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
    <description>Non-inferiority of immune response after 1 dose of Men ABCWY compared to 1 dose of Men ACWY-CRM in Experienced participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving an hSBA titer ≥ LLOQ for each secondary MenB test strain in Groups 1 and 3 combined</measure>
    <time_frame>At baseline and 1 month after Vaccination 2</time_frame>
    <description>Immune response for MenB, induced by 2 doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with hSBA titers ≥1:4, ≥1:8, ≥1:16, ≥1:32, ≥1:64, and ≥1:128 for each secondary MenB test strain in Groups 1 and 3 combined</measure>
    <time_frame>At baseline and 1 month after Vaccination 2</time_frame>
    <description>Immune response for MenB, induced by 2 doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for the secondary MenB test strains in Groups 1 and 3 combined</measure>
    <time_frame>At baseline and 1 month after Vaccination 2</time_frame>
    <description>Immune response for MenB, induced by 2 doses of MenABCWY</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">2413</enrollment>
  <condition>Meningococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>1-Immuno Subset (ACWY Naive,MenABCWY/Saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Naive subjects, MenABCWY/Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Naive subjects, Trumenba/MenACWY-CRM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Experienced subjects, MenABCWY/Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Experienced subjects, Trumenba/MenACWY-CRM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Safety Subset (ACWY Naive,MenABCWY/Saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Naive subjects, MenABCWY/Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Naive subjects, Trumenba/MenACWY-CRM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-Safety Subset (ACWY Experienced,MenABCWY/Saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Experienced subjects, MenABCWY/Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Experienced subjects, Trumenba/MenACWY-CRM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenABCWY</intervention_name>
    <description>N meningitidis groups A, B, C, W, and Y vaccine</description>
    <arm_group_label>1-Immuno Subset (ACWY Naive,MenABCWY/Saline)</arm_group_label>
    <arm_group_label>3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)</arm_group_label>
    <arm_group_label>5-Safety Subset (ACWY Naive,MenABCWY/Saline)</arm_group_label>
    <arm_group_label>7-Safety Subset (ACWY Experienced,MenABCWY/Saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1-Immuno Subset (ACWY Naive,MenABCWY/Saline)</arm_group_label>
    <arm_group_label>3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)</arm_group_label>
    <arm_group_label>5-Safety Subset (ACWY Naive,MenABCWY/Saline)</arm_group_label>
    <arm_group_label>7-Safety Subset (ACWY Experienced,MenABCWY/Saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trumenba</intervention_name>
    <description>Bivalent recombinant lipoprotein 2086 vaccine</description>
    <arm_group_label>2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_label>4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_label>6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_label>8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>Meningococcal group A, C, W-135, and Y conjugate vaccine</description>
    <arm_group_label>2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_label>4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_label>6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)</arm_group_label>
    <arm_group_label>8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject aged &gt;=10 and &lt;26 years at the time of randomization.&#xD;
&#xD;
          -  Healthy subject as determined by medical history, physical examination, and judgment&#xD;
             of the investigator.&#xD;
&#xD;
          -  Negative urine pregnancy test for all female subjects.&#xD;
&#xD;
          -  ACWY-naïve participants: Participants who have never received a prior dose of a&#xD;
             meningococcal vaccine containing ACWY serogroups.&#xD;
&#xD;
          -  ACWY-experienced participants: Participants who have received not more than 1 prior&#xD;
             dose, no sooner than 4 years prior to the date of randomization of Menactra or Menveo.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous vaccination with any meningococcal group B vaccine, any purely polysaccharide&#xD;
             (nonconjugate) meningococcal vaccine, or monovalent/bivalent meningococcal vaccine.-&#xD;
             Subjects receiving any allergen immunotherapy with a non-licensed product or receiving&#xD;
             allergen immunotherapy with a licensed product and are not on stable maintenance&#xD;
             doses.&#xD;
&#xD;
          -  A known or suspected defect of the immune system that would prevent an immune response&#xD;
             to the vaccine, such as subjects with congenital or acquired defects in B cell&#xD;
             function, those receiving chronic systemic (oral, intravenous, or intramuscular)&#xD;
             corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the&#xD;
             United States with terminal complement deficiency are excluded from participation in&#xD;
             this study.&#xD;
&#xD;
          -  Significant neurological disorder or history of seizure (excluding simple febrile&#xD;
             seizure).&#xD;
&#xD;
          -  Current chronic use of systemic antibiotics.&#xD;
&#xD;
          -  Participation in other studies involving investigational drug(s) or investigational&#xD;
             vaccine(s) within 28 days prior to study entry and/or during study participation.&#xD;
&#xD;
          -  Any neuroinflammatory or autoimmune condition, including, but not limited to,&#xD;
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.&#xD;
&#xD;
          -  History of microbiologically proven disease caused by N meningitidis or Neisseria&#xD;
             gonorrhoeae.&#xD;
&#xD;
          -  Receipt of any blood products, including immunoglobulin, within 6 months before the&#xD;
             first study vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC, Birmington Pediatric Assocaites</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Research Associates, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiel Family and Sports Medicine, PC/CCT Research</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research-Rancho Paseo Medical Group</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Madera Family Medical Group</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optumcare Colorado Springs, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ALL Medical Research, LLC</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida, an AMR company</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Crystal Biomedical Research, LLC</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Healthy Life Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bio-Medical Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complete Health Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oviedo Medical Research, LLC</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PAS Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Appalachian Clinical Research</name>
      <address>
        <city>Adairsville</city>
        <state>Georgia</state>
        <zip>30103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Chamblee</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saltzer Health</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83686</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MOC Research</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46544</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The South Bend Clinic Center for Research</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>Ankeny</city>
        <state>Iowa</state>
        <zip>50023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michael W. Simon, MD, PSC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acorn to Oak Pediatrics - ACC Pediatric Research</name>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skyline Medical Center, PC/CCT Research</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Fairfield, Inc.</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <zip>73099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liberty Family Practice</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charleston Pediatrics, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Pediatric Associates of Bristol, PC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol, LLC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Medicine Associates of Texas</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AIM Trials, LLC</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Texas Family Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olympus Family Medicine/CCT Research</name>
      <address>
        <city>Holladay</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Care</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SANARE s.r.o</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>37006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUDr. Katerina Stichhauerova s.r.o.</name>
      <address>
        <city>Pardubice</city>
        <zip>530 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicentrum 6 s.r.o.</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praktik Pb s.r.o.</name>
      <address>
        <city>Pribram</city>
        <zip>26101</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DRC Gyógyszervizsgáló Központ Kft.</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinTrial Audit Kft., Klinikai Farmakologiai Intezet, Vedooltasi Ambulancia</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coronella Orvosi Centrum / Trial Pharma Kft.</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Kft.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fejér Megyei Szent György Egyetemi Oktató Kórház</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych JCI</name>
      <address>
        <city>Krakow</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Przylądek Zdrowia</name>
      <address>
        <city>Krakow</city>
        <zip>30-644</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej &quot;Salmed&quot;</name>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Lecznictwa Ambulatoryjnego MICHALKOWICE</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital im. Sw. Jadwigi Slaskiej w Trzebnicy</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3511001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

